53 unknown, 39 completed, 11 recruiting, 9 not yet recruiting. 42 Not applicable, 33 Phase 2, 9 Phase 1, 9 Phase 3, 8 Phase 4.
Follow Eastern Hepatobiliary Surgery Hospital: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor Perform super-resolution ultrasound imaging on the study population - Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 350 | 2026-07-01 | 2026-07-16 | |
| Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer Sintilimab + GC, SBRT 7Gy✖️5 QD - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 123 | 2026-06-15 | 2026-06-10 |
| Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD Daidzein - Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 44 | 2026-05-21 | 2026-06-03 |
| A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma Organoid Drug Sensitivity Testing-Guided Therapy - Unresectable Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 94 | 2026-01-30 | 2026-01-20 |
| Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer Organoid Drug Sensitivity Testing-Guided Therapy - Hepatocellular Carcinoma Resectable | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 56 | 2026-01-30 | 2026-01-23 |
| A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers Organoid Drug Sensitivity Testing-Guided Therapy - Advanced Biliary Tract Cancer(BTC) | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 88 | 2026-01-30 | 2026-01-20 |
| A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer complex behavioral intervention - Primary Hepatocellular Carcinoma, Unresectable Liver Cancer | Not applicable | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 193 | 2026-01-01 | 2026-01-13 |
| The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD Sequential treatment of bevacizumab combined with atezolizumab (sequential group), Simultaneous treatment of bevacizumab combined with atezolizumab (same period group) - HCC - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 20 | 2025-10-20 | 2025-12-16 |
| Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC - Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI) | Recruiting | Chinese Academy of Sciences | 400 | 2025-09-01 | 2025-09-12 | |
| A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma Super Hi-TCR-T cells - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 30 | 2025-07-30 | 2025-09-03 |
| Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC Sintilimab, radiotherapy, TACE - Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 286 | 2025-07-10 | 2025-09-22 |
| QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors QL1706 - Biliary Tract Tumors | Phase 2 | Active not recruiting | Eastern Hepatobiliary Surgery Hospital | 59 | 2025-06-14 | 2026-08-24 |
| Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor - Metastatic Biliary Tract Cancer, HER2 Positive | Phase 4 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 35 | 2025-02-01 | 2025-02-10 |
| Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study Systemic chemotherapy combined with immunotherapy - Unresectable Biliary Tract Cancer, Dynamic Prediction Model | Recruiting | Zhongda Hospital | 332 | 2025-01-31 | 2025-02-27 | |
| HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC PD-L1 inhibitor, HAIC - ICC, Advanced Cancer | Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 50 | 2025-01-01 | 2026-01-23 |
| Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data Interventional therapies combined with or without systemic drugs - Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Recruiting | Zhongda Hospital | 198 | 2024-12-31 | 2025-02-27 | |
| Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma Pemigatinib and Durvalumab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 38 | 2024-08-01 | 2024-07-31 |
| Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC Cadonilimab+Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Withdrawn | Shanghai Zhongshan Hospital | 2024-05-31 | 2025-05-23 | |
| Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP) Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques, Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques - Prostate Adenocarcinoma, Localized Prostate Carcinoma | Not applicable | Recruiting | Shanghai Changzheng Hospital | 480 | 2024-01-08 | 2026-07-23 |
| Research on Post-Stroke Anticoagulation Strategies for Atrial Fibrillation Based on Left Atrial Appendage Flow Velocity Measured by Intracardiac Echocardiography (ICE) Intracardiac Echocardiography (ICE) for Differential Diagnosis - Atrial Fibrillation (AF) | Completed | Changhai Hospital | 172 | 2024-01-01 | 2026-02-27 |
Showing 20 of 118. Sign in to see all of them.
Carcinoma, Hepatocellular (59) · Gallbladder Neoplasms (12) · Cholangiocarcinoma (10) · Liver Neoplasms (7) · Liver Cirrhosis (6) · Biliary Tract Neoplasms (5) · Recurrence (5) · Pancreatic Neoplasms (4) · End Stage Liver Disease (3) · Bile Duct Neoplasms (2) · Bites and Stings (2) · Disease (2) · Hemorrhage (2) · Hepatitis B (2) · Klatskin Tumor (2)
Epirubicin (3) · Fluorouracil (3) · Hepatectomy (3) · Carvedilol (2) · Ethiodized Oil (2) · Hand Strength (2) · Nadroparin (2) · Neoadjuvant Therapy (2) · Oxaliplatin (2) · Radiofrequency Ablation (2) · Radiotherapy (2) · Sorafenib (2) · Tomography, X-Ray Computed (2) · metuximab (2) · sintilimab (2)
China (107) · Hong Kong (1) · Thailand (1)
Shen Feng, MD (7) · Feng Shen (5) · Feng Shen, MD (4) · Feng Shen, MD, PhD (4) · Daiming Fan (3) · Feng Shen, M.D. (3) · Shiyao Chen, Professor (3) · Gang Chen, MD,PhD (2) · Gao-Jun Teng, M.D (2) · Jiamei Yang, MD (2) · Jinlin Hou, MD (2) · Li Aijun, MD (2) · Ai-jun Li, M.D. (1)
PMID 10207464, PMID 12049862, PMID 12594571, PMID 12623635, PMID 12893895, PMID 16305946, PMID 17877488, PMID 18355796, PMID 18852074, PMID 19241423, PMID 19304921, PMID 19453695, PMID 19560026, PMID 19926229, PMID 20175033, PMID 21966941, PMID 22173160, PMID 22190656, PMID 22353262, PMID 22544225, PMID 22766484, PMID 23216261, PMID 23399463, PMID 23482806, PMID 24410841, PMID 24935203, PMID 25139639, PMID 25516662, PMID 25559415, PMID 26148053, PMID 26850262, PMID 29129627, PMID 29448045, PMID 31672853, PMID 31774468, PMID 32164877, PMID 33593763, PMID 34268122, PMID 35303509, PMID 38110372, PMID 38619136, PMID 41780001, PMID 42542210, PMID 42632422